Merck
  • Home
  • Search Results
  • Placental fractalkine is up-regulated in severe early-onset preeclampsia.

Placental fractalkine is up-regulated in severe early-onset preeclampsia.

The American journal of pathology (2015-03-15)
Monika Siwetz, Martina Dieber-Rotheneder, Mila Cervar-Zivkovic, Daniel Kummer, Julia Kremshofer, Gregor Weiss, Florian Herse, Berthold Huppertz, Martin Gauster
ABSTRACT

The pathogenesis of preeclampsia (PE) includes the release of placental factors into the maternal circulation, inducing an inflammatory environment in the mother. One of the factors may be the proinflammatory chemokine fractalkine, which is expressed in the syncytiotrophoblast of human placenta, from where it is released into the maternal circulation by constitutive shedding. We examined whether placental fractalkine is up-regulated in severe early-onset PE and whether the proinflammatory cytokines tumor necrosis factor (TNF)-α and IL-6 are able to increase the expression of fractalkine. Gene expression analysis, enzyme-linked immunosorbent assay, and immunohistochemistry consistently showed increased fractalkine expression in placentas from severe early-onset PE, compared to gestational age-matched controls. Expression of a disintegrin and metalloproteinases (ADAMs) 10 and 17, which convert transmembrane fractalkine into the soluble form, was significantly increased in these cases. Incubation of first-trimester placental explants with TNF-α provoked a significant increase in fractalkine expression and release of the soluble form, whereas IL-6 had no effect. TNF-α-mediated up-regulation of placental fractalkine was reversed in the presence of the aspirin-derivative salicylate, which impaired activation of NF-κB p65 in TNF-α-treated explants. On the basis of data from placental explants, we suggest that increased maternal TNF-α may up-regulate the expression and release of placental fractalkine, which, in turn, may contribute to an exaggerated systemic inflammatory response in PE.

MATERIALS
Product Number
Brand
Product Description

SAFC
BIS-TRIS
SAFC
BIS-TRIS
Sigma-Aldrich
IL-6 human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human CX3CL1
Sigma-Aldrich
BIS-TRIS, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
Sodium salicylate, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Sodium salicylate, meets USP testing specifications
Sigma-Aldrich
BIS-TRIS, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
BIS-TRIS, ≥98.0% (titration)
Sigma-Aldrich
BIS-TRIS, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Sodium salicylate, puriss. p.a., ≥99.5% (NT)
Sigma-Aldrich
Sodium salicylate, puriss. p.a., reag. Ph. Eur., 99.5-101.0% (calc. to the dried substance)
Sigma-Aldrich
Interleukin-6 human, IL-6, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Interleukin-6 human, IL-6, recombinant, expressed in HEK 293 cells, suitable for cell culture
Sigma-Aldrich
Interleukin-6 human, IL-6, recombinant, expressed in E. coli, Carrier Free